ConductScience.org, home

Paper3396010

Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.

Muraro R and 9 others. Cancer Res, 1988. Cited by 259 papers, by iCite.

Cite this record

ConductScience Library. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Papers, record 3396010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3396010

Download JSON
Cell line
B72.33 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
PubMed
Journal
Cancer Res
PubMed
Year
1988
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
259
iCite
Relative citation ratio, by iCite
8.48
iCite
Revised in PubMed
2004-11-17
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Muraro RR
2Kuroki MM
3Wunderlich DD
4Poole DJD J
5Colcher DD
6Thor AA
7Greiner JWJ W
8Simpson JFJ F
9Molinolo AA
10Noguchi PP

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antigens, NeoplasmMajor topic
GlycoproteinsMajor topic
Animals
Antigens, Surface
Breast Neoplasms
Colonic Neoplasms
Female
Humans
Immunohistochemistry
Mice
Mice, Inbred BALB C
Radioimmunoassay

Source PubMed

Download CSV of topics

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 259 citations.

PMIDTitleJournalYearIn PapersSource
42780573Carbohydrate antigen 72-4 and tumor-associated glycoprotein 72 - tumor marker: Past, present and future.World J Gastrointest Pathophysiol2026https://conductscience.org/library/papers/42780573PubMed
42677388From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chem Rev2026https://conductscience.org/library/papers/42677388PubMed
42340347Cancer-associated alterations in O-GalNAc glycosylation.Glycobiology2026https://conductscience.org/library/papers/42340347PubMed
40925376Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors.Cell Rep Med2025https://conductscience.org/library/papers/40925376PubMed
40361381Development and Potent Anti-Tumor Activity of a Fully Humanized Anti-TAG-72-IL-2 Fusion Protein for Therapy of Solid Tumors.Cancers (Basel)2025https://conductscience.org/library/papers/40361381PubMed
40169149Antibody numbering schemes: advances, comparisons and tools for antibody engineering.Protein Eng Des Sel2025https://conductscience.org/library/papers/40169149PubMed
37614264Prognostic Value of Tumor Markers in Gastric Cancer: A Tertiary Cancer Centre Experience.Cureus2023https://conductscience.org/library/papers/37614264PubMed
37509200Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors.Cancers (Basel)2023https://conductscience.org/library/papers/37509200PubMed
37305274Deciphering Protein O-GalNAcylation: Method Development and Disease Implication.ACS Omega2023https://conductscience.org/library/papers/37305274PubMed
37284439Smaller size packs a stronger punch - Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigens.Theranostics2023https://conductscience.org/library/papers/37284439PubMed
36686742The (Sialyl) Tn antigen: Contributions to immunosuppression in gastrointestinal cancers.Front Oncol2022https://conductscience.org/library/papers/36686742PubMed
35158915Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.Cancers (Basel)2022https://conductscience.org/library/papers/35158915PubMed
34950576Survival Advantage Following TAG-72 Antigen-Directed Cancer Surgery in Patients With Colorectal Carcinoma: Proposed Mechanisms of Action.Front Oncol2021https://conductscience.org/library/papers/34950576PubMed
33614914Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer.Mol Ther Oncolytics2021https://conductscience.org/library/papers/33614914PubMed
32620701TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody.J Nucl Med2021https://conductscience.org/library/papers/32620701PubMed
32368864Improved targeting of an anti-TAG-72 antibody drug conjugate for the treatment of ovarian cancer.Cancer Med2020https://conductscience.org/library/papers/32368864PubMed
32308758Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology.Theranostics2020https://conductscience.org/library/papers/32308758PubMed
30510550Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.Front Immunol2018https://conductscience.org/library/papers/30510550PubMed
28513912Improving theranostics in pancreatic cancer.J Surg Oncol2017https://conductscience.org/library/papers/28513912PubMed
26270678Challenges in Antibody Development against Tn and Sialyl-Tn Antigens.Biomolecules2015https://conductscience.org/library/papers/26270678PubMed

See all 45 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3396010

GET https://conductscience.org/api/papers/v1/3396010/cited_by?page=2